First Episode Psychosis Clinical Trial
Official title:
A Randomised, Double Blind Pilot Study of Minocycline and Placebo Added to Treatment-as-Usual (TAU) in First-Episode Psychosis
The purpose of this study is to determine whether the addition of minocycline or placebo to
treatment as usual (TAU):
1. prevents the accumulation of negative symptoms and intellectual decline following a
first episode of non-affective psychosis; and
2. whether minocycline stabilizes the efficacy of antipsychotics.
Background:
There is increasing clinical, neuropsychological and imaging evidence that schizophrenia
involves a progressive process at the time of the first episode and later in life. However,
it is not clear which systems are affected nor in which parts of the brain. In two Stanley
first episode cohorts at Manchester (Stirling et al, 2004,) and in a group of elderly
patients with schizophrenia (Gabrovska-Johnson et al 2004), evidence of deterioration in
visuo-spatial functions has been found. This implies a right-hemisphere pathology. Other
evidence suggests that the initiation of schizophrenia may involve left-sided pathology
(Lawrie et al 2002) so it could be that right hemisphere pathology may follow left and give
rise to the deficits of chronic schizophrenia (Gabrovska-Johnson et al 2004). If so, early
treatment with a neuroprotective agent might prevent the accumulation of deficit symptoms
and cognitive impairment.
Minocycline is a tetracycline antibiotic with proven long-term high dose safety in humans,
is routinely used to treat acne and rheumatoid arthritis demonstrating that it acts as a
non-steroidal anti-inflammatory, as well as an antimicrobial drug. Minocycline, unlike
tetracycline, crosses the blood-brain barrier. This and related compounds show
neuroprotective properties in rat models of ischemic brain damage, in glutamate
neurotoxicity in cell cultures and in a rat model of Huntington's disease in which it slowed
progression (Chen et al, 2000; Yrjanheikki et al, 1999). Minocycline delays disease onset
and extends survival in amyotrophic lateral sclerotic mice (Shan Zhu et al 2002).
Minocycline has various properties including inhibition of capsases, inhibition of
microglial activation, reduced cyclooxygenase-2 expression and reduced prostaglandin E (2)
formation. Furthermore, it inhibits the formation of inducible nitric oxide - a mechanism of
glial activation. All these mechanisms have been implicated in schizophrenia. All these
mechanisms have been implicated in schizophrenia.
Because of its broad spectrum of action, we consider minocycline is an important candidate
molecule for the prevention of deterioration in schizophrenia. Based on the evidence so far
we propose a randomised double blind placebo controlled study of minocycline added to
treatment-as-usual (TAU) in first-episode psychosis.
Study Hypotheses:
- A neurodegenerative process, initially most marked in the left hemisphere, in late
adolescence is responsible for the onset of schizophrenia in those at risk.
- Continuation of this process after onset and its extension to the right hemisphere
causes accumulation of deficit symptoms and cognitive decline.
- Glutamate antagonism may enhance the antipsychotic effects of dopamine receptor
blockade and prevent attenuation of efficacy with long-term treatment.
TREATMENT:
Minocycline is a widely available antibiotic given in doses of 50mg twice daily increasing
to 200mgs per day. It has been used very widely and appears to be tolerated well. The study
advisor, Dr. Serdar Dursun, has used doses of up to 200mg per day in the treatment of
Huntington's disease (Denovan-Wright et al 2002).
It is widely available in Pakistan and Brazil and given in doses of 50mg twice daily
increasing to 100mg twice daily (in total 200mg per day) (British National Formulary: BNF
maximum dose 200mg per day). As per counselling recommendations in the British National
Formulary: "minocycline medication should be swallowed whole with plenty of fluid while
sitting or standing", to allow effective absorption. Patients will be counselled that 'the
study medication should be swallowed whole with plenty of fluid while standing or sitting.'
Patients will be informed regarding reported side-effects as cited in the BNF these include;
nausea, vomiting, diarrhoea, dysphagia, oesophageal irritation, anorexia, dizziness,
tinnitus, vertigo, hypersensitivity reactions (rash, exfoliative dermatitis, urticaria,
angioedema, anaphylaxis, pericarditis), headache, visual disturbances, hepatotoxicity,
pancreatitis, antibiotic associated colitis, blood dyscrasias, exacerbation of systemic
lupus erythematosus and myasthenia gravis, rarely photosensitivity, skin, teeth,
conjunctiva, tears and sweat discoloration.
NUMBER OF PATIENTS:
Using data from the SOCRATES study, we are able to calculate that 40 patients per treatment
arm will detect a group difference on the primary outcome measure, i.e, PANSS, giving a 85%
chance of detecting a difference between treatment groups of 4 points. The power estimate is
likely to be conservative as there are three treatment groups. The automated CSF measures
will detect a 5% group difference with these sample sizes. A minimum of 52 completed
patients will be necessary (26 completed patients per treatment group).
Study Advisors:
Prof Bill Deakin(design), Prof Serdar Dursun(scientific), Prof Shon Lewis (clinical), Dr
John Stirling (cognition), Dr Paul Richardson (cognition), Prof Graham Dunn (analysis).
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04298450 -
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
|
N/A | |
Completed |
NCT00202280 -
Efficacy of Treating First Episode Psychosis With Folic Acid,B12 and B6 in Addition to Antipsychotic Medication
|
Phase 2/Phase 3 | |
Completed |
NCT01026584 -
Efficacy and Safety of Aripiprazole in First Episode Psychosis
|
Phase 4 | |
Completed |
NCT03983421 -
Feasibility of an Early Detection Program for Early Psychosis on a College Campus
|
||
Recruiting |
NCT04046497 -
Artificial Intelligence to Measure Adherence to Oral Medication
|
Phase 4 | |
Withdrawn |
NCT04369677 -
Thermoregulation Among Individuals With First-episode Psychosis
|
||
Completed |
NCT03568500 -
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
|
Phase 4 | |
Completed |
NCT03102151 -
Reducing the Duration of Untreated Psychosis
|
||
Recruiting |
NCT05310838 -
Optimizing Engagement in Services for First-Episode Psychosis
|
N/A | |
Completed |
NCT03501160 -
Socially Inappropriate Behaviour in People With First Episode Psychosis: A Caregivers' Perspective
|
||
Recruiting |
NCT03196128 -
Early Intervention Psychosis Communication and Engagement Trial
|
N/A | |
Recruiting |
NCT04005378 -
Disengagement in CSC: Identifying Those at Risk and Addressing Their Needs
|
Phase 4 | |
Recruiting |
NCT03919760 -
Early Psychosis Intervention - Spreading Evidence-based Treatment
|
||
Completed |
NCT03409393 -
Feasibility and Relevance of High-Intensity Functional Training in Patients With First-Episode Psychosis
|
N/A | |
Completed |
NCT01753284 -
First Episode Psychosis and Pathway to Care in Nordland
|
||
Completed |
NCT01157585 -
Efficacy and Safety of Paliperidone ER in First Episode Psychosis
|
Phase 4 | |
Completed |
NCT05737966 -
Evaluation of Case Management for First Episode Psychosis Using the PEPsy-CM Checklist
|
||
Recruiting |
NCT04021719 -
OnTrackNY's Learning Healthcare System
|
||
Recruiting |
NCT04889911 -
Pilot RCT of Self-stigma Treatment for First Episode Psychosis
|
N/A | |
Recruiting |
NCT04853485 -
Repetitive Transcranial Magnetic Stimulation in Early Psychosis and The Functional Connectivity Biotypes
|
N/A |